See the DrugPatentWatch profile for cosentyx

The question at hand is whether higher doses of Cosentyx improve obese patient outcomes. To answer this, we must first understand what Cosentyx is and its intended use. Cosentyx, also known as secukinumab, is a medication used to treat several types of inflammatory diseases, such as plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis [1]. It belongs to a class of drugs called monoclonal antibodies, which work by targeting and blocking specific proteins involved in the body's immune response [1].

Now, let's examine the relationship between Cosentyx dosage and obese patient outcomes. According to a study published in the Journal of the American Academy of Dermatology, there is no significant difference in the efficacy of Cosentyx between obese and non-obese patients with psoriasis [2]. This study compared the clinical response of obese and non-obese patients receiving either 300 mg or 150 mg of Cosentyx every four weeks for 12 weeks [2]. The results showed no significant difference in Psoriasis Area and Severity Index (PASI) scores between obese and non-obese patients in both the 300 mg and 150 mg dose groups [2].

However, it is important to note that obesity may affect drug metabolism and distribution, potentially leading to altered drug exposure and efficacy [3]. Therefore, individualized dosing based on a patient's body weight or other factors may be necessary to optimize treatment outcomes [3].

In summary, based on the available information, there is no evidence to suggest that higher doses of Cosentyx improve obese patient outcomes compared to non-obese patients. Individualized dosing based on a patient's specific needs may be more appropriate to optimize treatment outcomes.

Sources:
[1] "Cosentyx (secukinumab) Injection, for Subcutaneous Use." U.S. Food and Drug Administration, FDA, www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/cosentyx-secukinumab-injection-subcutaneous-use.
[2] Blauvelt, Andrew, et al. "Secukinumab 300 mg Is Efficacious in Obese and Nonobese Patients with Psoriasis: Post Hoc Analysis of a Phase 3 Randomized Clinical Trial." Journal of the American Academy of Dermatology, Elsevier, 26 Jan. 2021, www.jaad.org/article/S0190-9622(20)32621-4/fulltext.
[3] "Obesity and Drug Therapy: More Than Just a Dose Adjustment." Mayo Clinic Proceedings, Elsevier, 1 Jan. 2015, www.mayoclinicproceedings.org/article/S0025-6196(14)01033-2/fulltext.